Analysts Set Expectations for Fennec Pharmaceuticals Inc’s Q4 2024 Earnings (NASDAQ:FENC)

Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Analysts at Capital One Financial issued their Q4 2024 earnings estimates for Fennec Pharmaceuticals in a research note issued on Thursday, May 2nd. Capital One Financial analyst N. Quibria forecasts that the company will post earnings of $0.06 per share for the quarter. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.11 per share.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.12). The firm had revenue of $9.74 million for the quarter, compared to analysts’ expectations of $9.47 million.

FENC has been the topic of a number of other reports. HC Wainwright raised their price objective on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Craig Hallum lifted their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $16.00 price objective on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.

Fennec Pharmaceuticals Stock Up 2.9 %

NASDAQ FENC opened at $9.35 on Monday. The stock’s 50-day simple moving average is $10.07 and its two-hundred day simple moving average is $9.58. Fennec Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $11.92. The company has a market capitalization of $255.44 million, a price-to-earnings ratio of -15.33 and a beta of 0.45.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its stake in shares of Fennec Pharmaceuticals by 107.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company’s stock valued at $34,000 after buying an additional 1,578 shares during the period. Hartford Financial Management Inc. raised its holdings in Fennec Pharmaceuticals by 4.4% in the 4th quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock worth $531,000 after purchasing an additional 2,000 shares in the last quarter. Gendell Jeffrey L lifted its position in shares of Fennec Pharmaceuticals by 0.9% in the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock worth $2,148,000 after purchasing an additional 2,579 shares during the period. Eudaimonia Advisors LLC boosted its stake in shares of Fennec Pharmaceuticals by 8.2% during the 1st quarter. Eudaimonia Advisors LLC now owns 35,359 shares of the company’s stock valued at $393,000 after purchasing an additional 2,673 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Fennec Pharmaceuticals during the 3rd quarter valued at about $50,000. Institutional investors own 55.51% of the company’s stock.

Insider Transactions at Fennec Pharmaceuticals

In related news, COO Adrian Haigh sold 22,222 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $10.30, for a total transaction of $228,886.60. Following the transaction, the chief operating officer now directly owns 22,222 shares in the company, valued at approximately $228,886.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Fennec Pharmaceuticals news, CFO Robert Andrade sold 13,975 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $11.00, for a total value of $153,725.00. Following the transaction, the chief financial officer now owns 105,746 shares in the company, valued at $1,163,206. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Adrian Haigh sold 22,222 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $10.30, for a total transaction of $228,886.60. Following the sale, the chief operating officer now owns 22,222 shares of the company’s stock, valued at $228,886.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 193,093 shares of company stock worth $1,984,921. Company insiders own 11.25% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.